Skip to contentpdufa.bio
Home › Decisions › CAPR 2026-11-20

CAPR FDA decision: announced Nov 20, 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

Goal date moved: 2026-08-22 → 2026-11-22 (recorded 2026-08-24). The FDA extended the goal date from 2026-08-22 to 2026-11-22 after Capricor's BLA amendment; Capricor announced the extension on 2026-08-24 and /pdufa-date-changes records it.

Both Capricor CRLs, from the primary sources: the FDA's letter beside the company's statements, with a dated timeline.

✕ COMPLETE RESPONSE LETTER

Verified against: FDA action day not found in a public FDA record · Announcement November 20, 2026 (Capricor Therapeutics press release) · Goal date November 22, 2026 (Capricor press release).

This page was first committed to pdufa.bio's public repository on Nov 21, 2026, 9:14 AM ET (public commit 012d17f). Dates on this page are the FDA's and the sponsor's; this line is ours.

Capricor announced on November 20, 2026 that it received a Complete Response Letter on its resubmitted BLA for deramiocel in Duchenne muscular dystrophy; the goal date was November 22, and the release does not date the letter.

Run-up into the decision (T-120 → T+0)

move day 11/20/26$30.4$3.856/2/26move day 11/20/26$30.4$3.856/2/26
Daily close, T-120 (6/2/26) through T+0. Run-up high $30.4 on 6/25/26, low $3.85 on 7/31/26 (T-120 to T-1). Decision announced 11/20/26. Historical price action, not a forecast.

Key facts

FDA decision datenot found in a public FDA record
Announced2026-11-20, after the close
OutcomeCRL
Drug / candidateDeramiocel (CAP-1002)
IndicationDuchenne muscular dystrophy (resubmitted BLA; HOPE-3)
CompanyCapricor Therapeutics Inc.
Market-cap tierSmall
120-day run-up (T-120→T-1)-73.6%
Decision-day move+0.8%
Move measured on2026-11-20 close, against the 2026-11-19 close; the news came after this close, so the move does not include the reaction to it
Cohort decision-day move (history)3.6% median (n=150)

Capricor announced on the evening of November 20, 2026 (7:55 PM ET) that it received a Complete Response Letter for its resubmitted BLA for deramiocel, its cell therapy for Duchenne muscular dystrophy (Capricor's announcement). Per Capricor, the letter states that the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites certain other clinical deficiencies; Capricor said it is reviewing the letter and will share next steps after its evaluation. The PDUFA goal date was November 22, 2026, moved from August 22 after a major amendment to the application (Capricor, August 24, 2026). The release does not state the letter's own date, so no early or late margin is given. This is deramiocel's second Complete Response Letter; the first was announced on July 11, 2025 (CAPR, July 11, 2025). A Complete Response Letter means the FDA will not approve the application in its present form; the sponsor can resubmit.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: Capricor Therapeutics press release, November 20, 2026

Specialist biotech funds holding CAPR, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management3,014,183$28.5 millionfiled November 16, 2026
EcoR1 Capital1,376,580$13.0 millionfiled November 16, 2026
Perceptive Advisors850,000$8.0 millionfiled November 16, 2026
RTW Investments250,000$2.4 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

Was deramiocel approved by the FDA?

No. Capricor announced on November 20, 2026 that the FDA issued a Complete Response Letter on its resubmitted BLA for deramiocel in Duchenne muscular dystrophy. Per Capricor, the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites certain other clinical deficiencies.

Which company is behind Deramiocel (CAP-1002)?

Deramiocel (CAP-1002) is a Capricor Therapeutics Inc. (CAPR) program. The company announced the FDA decision on November 20, 2026; the company's own announcement is linked on this page.

How did CAPR stock trade into the FDA decision?

Measured over the 120 trading days before the decision (T-120 to T-1), CAPR moved -73.6%. That is the recorded price path into this specific event. Historical measurement, not a prediction, and not investment advice.

Was the deramiocel decision before the PDUFA date?

Capricor announced the letter on November 20, two days before the November 22, 2026 goal date. Its release does not state the letter's own date, so pdufa.bio does not state an early or late margin.

Is this the first CRL for deramiocel?

No. Capricor announced an earlier Complete Response Letter for deramiocel on July 11, 2025, and then resubmitted the application.